Mod­er­na de­creas­es mR­NA pro­duc­tion with Lon­za in Switzer­land, brings some man­u­fac­tur­ing in-house

Last year
Pharma
Manufacturing

In­cyte ad­vances its Opzelu­ra eczema cam­paign with a ‘reimag­ine’ theme  

Last year
Pharma
Marketing

Elon Musk's brain-com­put­er pro­gram be­gins re­cruit­ing paral­y­sis pa­tients

Last year
R&D
Pharma

FDA wants to know: What's hold­ing up the de­vel­op­ment of in­di­vid­u­al­ized cell and gene ther­a­pies?

Last year
Cell/Gene Tx
FDA+

FDA un­der­scores qual­i­ty, safe­ty con­cerns with Intar­cia’s di­a­betes treat­ment ahead of ad­comm

Last year
Pharma
FDA+

Seelos' stock plunges by over 75% af­ter ke­t­a­mine drug for sui­cide pre­ven­tion fails a PhII tri­al

Last year
R&D

Rel­ma­da’s ma­jor de­pres­sion drug shows PhI­II promise in a fresh batch of pa­tients

Last year
R&D

Genen­tech gets gluey, pay­ing $47M up­front to Ori­o­n­is for de­grad­er dis­cov­ery deal

Last year
Deals

Ox­ford Bio­med­ica piv­ots by lay­ing off 200 peo­ple, ac­quir­ing ABL Eu­rope amid de­clin­ing to­tal rev­enues

Last year
People
Manufacturing

Atara to file T cell im­munother­a­py in the US in 2024; Rayze­Bio clos­es $358M IPO

Last year
News Briefing

UCB's Eu­rope-ap­proved IL-17 au­toim­mune drug hits FDA de­lay

Last year
R&D
FDA+

Taysha stops de­vel­op­ing a gene ther­a­py amid de­bate over FDA’s stance on ul­tra-rare tri­als

Last year
R&D
Cell/Gene Tx

NightHawk lays off 14% of R&D work­force, piv­ots to fo­cus on CD­MO Scor­pius Bio­man­u­fac­tur­ing

Last year
People
Manufacturing

Benev­o­len­tAI, Ex­sci­en­tia on the come­back trail af­ter se­cur­ing sep­a­rate AI drug dis­cov­ery deals with Mer­ck KGaA

Last year
Deals
AI

These are biotech's 44 most promis­ing star­tups of the last half-decade — here's how they've end­ed up

Last year
Special

It’s al­most the end of the road for Fresh Tracks as board sup­ports liq­ui­da­tion

Last year
People
Pharma

Up­dat­ed: Roche’s Genen­tech wades in­to ra­dio­phar­ma­ceu­ti­cals with Pep­tiDream al­liance, $40M up­front

Last year
Deals

FDA re­jects first nasal spray al­ter­na­tive to EpiPen for those with se­vere al­ler­gies

Last year
FDA+

Tol­re­mo rais­es $39M Se­ries A to ad­vance drug de­signed to dis­man­tle ear­ly can­cer de­fens­es

Last year
Financing
Startups

Ther­mo Fish­er is ready to ex­pand its vi­ral vec­tor pro­duc­tion site in Mass­a­chu­setts once there’s ‘de­mand for it’

Last year
Pharma
Manufacturing

Chi­nese im­ports of com­mon can­cer drug run dry, FDA says

Last year
FDA+
Manufacturing

Eli Lil­ly sues com­pounders and med­ical spas over sales of un­ap­proved copy­cats of its di­a­betes block­buster Moun­jaro

Last year
Pharma
Law

House law­mak­ers press CMS on mon­i­tor­ing re­bate in­for­ma­tion, tout PBM re­forms at hear­ing

Last year
Pharma
FDA+

Al­ler­gan on the hook for $160M for hy­dro­cor­ti­sone ‘abuse of dom­i­nance,’ UK court rules

Last year
Pharma
Law
First page Previous page 277278279280281282283 Next page Last page
A service from the Financial Times